Our data is publicly available at GEO depository number GSE103412 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103412>).

Introduction {#sec004}
============

Treatment-related toxicity remains a major concern in patients with head and neck cancers \[[@pone.0190709.ref001],[@pone.0190709.ref002]\], including squamous cell cancer of the tonsil (TSCC). The incidence of TSCC is increasing, due to a shift towards younger patients with human papilloma virus (HPV)-positive cancers \[[@pone.0190709.ref003],[@pone.0190709.ref004]\]. Consequently, more survivors must live with both short- and long-term cancer treatment side effects, including mucositis, hypo-salivation, tissue fibrosis, and hypo-vascular bone \[[@pone.0190709.ref005]--[@pone.0190709.ref008]\].

For curative intentions, radiation therapy (RT) is a key modality, with or without surgery, combined with concomitant chemotherapy. Squamous cell carcinomas require a relatively large amount of radiation (60 to 70 Gray \[Gy\]) \[[@pone.0190709.ref009]\]. Recently, outcomes have improved with the advent of radio-sensitizers and intensity-modulated RT. However, mucositis remains an acute, painful side effect \[[@pone.0190709.ref010]\]. Mucositis appears clinically at a total dose of approximately 35 Gy (after about 2 weeks), and it gradually worsens with each dose delivered \[[@pone.0190709.ref011]\]. The incidence of mucositis is 85% in patients with head and neck cancers that require RT; of these, 37% require hospitalization, and of these 51% require a feeding tube \[[@pone.0190709.ref005],[@pone.0190709.ref006]\]. The lack of predictability of who are severely affected is a significant clinical challenge \[[@pone.0190709.ref012]\]. Palliative interventions may relieve the side effects, but no preventive medications are available that can reduce mucositis, and no markers are available for pretreatment identification of patients likely to be severely affected \[[@pone.0190709.ref013]\]. Previous studies have shown that RT causes DNA damage and oxidative stress, which subsequently lead to activation of p53-induced radiotoxic pathways, apoptosis, and cell-cycle arrest \[[@pone.0190709.ref014]--[@pone.0190709.ref016]\]. Furthermore, DNA repair and damage response via MDM2 suppression of p53, was also reported a consequence of RT in addition to radiation fibrosis, and endothelial damage \[[@pone.0190709.ref017]--[@pone.0190709.ref018]\]. However, no studies have described a gene expression analysis of human mucosa \[[@pone.0190709.ref019]\].

Here, we describe a disease- and treatment-specific global gene expression (GGE) pilot study. We examined consecutive mucosa biopsies and peripheral blood cells collected from patients with TSCC during RT treatment. This study aimed to generate phenotypic data to document the feasibility of a novel in vivo model of consecutive human biopsies during RT treatment that might provide new biological knowledge of the molecular pathogenesis of severe mucositis and facilitate the identification of potential predictive biomarkers.

Materials and methods {#sec005}
=====================

Patients {#sec006}
--------

The Committee on Health Research Ethics of the Northern Denmark Region (N-20100022) approved the clinical protocol for this study. Informed written consent was obtained from all patients, in accordance with the Declaration of Helsinki. Patients were enrolled from September 1, 2010, to April 30, 2013. Inclusion criteria were age ≥18 years, cancer-treatment naïve, and without uncontrolled competitive disease.

We recruited 19 patients at the Department of Maxillofacial Surgery, Aalborg University Hospital. Among those patients, nine displayed histologically confirmed TSCC and a metastasis-negative FDG-PET/CT scan. Of these nine patients, seven provided three consecutive buccal biopsies and peripheral blood samples. The first biopsy and blood sample set (baseline) was acquired before the start of RT, the second set was acquired after one week of RT, and the third set was acquired at an average of 20 days after the last RT, for outline of the study plan ([Fig 1](#pone.0190709.g001){ref-type="fig"}). Two of the nine included patients died during treatment; one after the second biopsy and one before the first biopsy. The patient that died after the second biopsy was included in the analysis; thus, we analyzed eight patient samples. Our control group comprised 10 healthy, non-smoking individuals that had participated in a previous study \[[@pone.0190709.ref020]\]. Of these, one was excluded, due to an autoimmune disease that was not reported at the time of biopsy; thus, nine control samples were analyzed. All patients underwent pretreatment evaluations, including a medical history, smoking habits (smokers were defined as smoking more than 10 cigarettes per day), alcohol consumption (consumers were defined as drinking more than 21 units of alcohol weekly), and a clinical examination. Baseline characteristics were noted, including age, gender, and Eastern Cooperative Oncology Group (ECOG) performance status. Before RT, patients were screened for dental infections, and when indicated, infections were eradicated.

![The pilot study design.\
Tissue samples were collected from patients with tonsil squamous cell cancer (TSCC) at three time points: at baseline, before RT (Day0), after 7 days of RT (Day7), and 20 days after the last RT. In addition, tissue samples were collected from healthy subjects (CON). All tissue collections consisted of one blood sample and one biopsy of oral buccal mucosa. Tissue samples were successively stored in our biobank. Once all the material was collected, gene expression analysis was performed collectively at the same laboratory.](pone.0190709.g001){#pone.0190709.g001}

TSCC tumors were staged according to the TNM system for staging cancer (T = size of primary tumor; N = presence and level of lymph node involvement; M = presence of distant metastasis) \[[@pone.0190709.ref021]\]. Immunohistochemistry was performed to detect p16 overexpression in the tumor, which indicated HPV-induced TSCC. All patients with TSCC received intention-to-cure treatments. Accelerated external RT was applied in 6 weekly fractions of 2 Gy. RT was supplemented, when indicated, with concomitant cisplatin (40 mg/m^2^) once weekly during RT, according to international guidelines \[[@pone.0190709.ref022],[@pone.0190709.ref023]\]. We noted the total radiation dose (Gy) applied to the tumor, based on the radiation schemes. We also calculated the estimated dose applied to the buccal mucosa at the site of the biopsy.

Mucositis assessment {#sec007}
--------------------

Oral mucositis (OM) was evaluated weekly in all patients, by the same researcher (MM), according to the World Health Organization oral toxicity assessment worksheet \[[@pone.0190709.ref024]\]. Subjective symptoms (pain and ability to eat solid food) and objective oral mucositis-related findings (erythema, ulceration) were noted. Grades 0 and 1 comprised none/mild mucositis (NM); this included soreness, with or without erythema, but solid food could be taken. Grades 2 to 4 comprised ulcerative mucositis (UM); in UM, food intake gradually declined, due to pain, and parenteral feeding might become necessary. The highest score measured during treatment was noted as the patients general mucositis experience.

Collection of mucosa tissue and blood cells {#sec008}
-------------------------------------------

Sample collection was performed with the methods described previously \[[@pone.0190709.ref020]\]. Briefly, a lens-formed, 5-mm biopsy was harvested with a scalpel from the buccal mucosa approximately 1 cm inferior to the parotid papilla in a standardized manner, and the wound was tightly sutured. One half of the biopsy was immediately embedded in RNA*later*™, for GGE analysis. The other half was fixed in formalin and embedded in paraffin for immunohistochemistry.

Within 2 h of the biopsy procedure, 15 ml of EDTA-mixed venous full blood was collected. Then, mononuclear cells were isolated and stored at -196°C in liquid nitrogen, until analysis.

Gene expression analysis {#sec009}
------------------------

Gene expression was evaluated with the methods described previously in detail \[[@pone.0190709.ref020]\]. Briefly, for both mononuclear cells and mucosa, we used the Affymetrix GeneChip Human Exon 1.0 ST Arrays with the Affymetrix GeneChip WT Terminal Labeling and Controls Kit (P/N 901524). CEL files were generated with Affymetrix GeneChip Command Console Software and deposited in the NCBI Gene Expression Omnibus repository, under number GSE103412.

Immunohistochemistry {#sec010}
--------------------

Tissue blocks were cut in 4-μm sections, and the sections were mounted on glass slides. With an in-house optimized protocol, tissues were stained for scinderin with a rabbit polyclonal antibody (KIAA1905, Nordic Biosite, [www.nordicbiosite.com](http://www.nordicbiosite.com/)). Stained slides were scanned on a Hamamatsu NanoZoomer slide scanner and analyzed with NDP viewer software. To estimate the scinderin stain intensity, each stained slide was viewed at a magnification of ×15, and evaluated within a framed rectangle of 0.75 × 0.4 mm (0.3 mm^2^). Samples were classified as no stain (0), lightly stained (+), or heavily stained (++).

Statistical analysis {#sec011}
--------------------

All statistical analyses were performed with R \[[@pone.0190709.ref025]\] version 3.2.2 and Bioconductor packages \[[@pone.0190709.ref026]\].

### Estimation of sample size {#sec012}

We applied the method described by Lee and Whitmore to identify genes that varied more than two-fold between test points, with a false discovery rate (FDR) less than 0.05% and a power of 90% \[[@pone.0190709.ref027]\]. This analysis was implemented in the R-package, size-power (Qui 2008). The results indicated that 10 patients in each group would provide sufficient statistical power.

### Data preprocessing {#sec013}

The CEL files produced by the Affymetrix Expression Console were preprocessed and summarized at the gene level with the RMA algorithm in the Bioconductor package, affy, based on custom CDF-files \[[@pone.0190709.ref028]\]. This preprocessing step revealed the expression levels of 38,830 genes for each exon array. Genes were annotated with Ensembl gene identifiers.

### Detection of differential expression {#sec014}

With the patient ID as a cluster variable, we used the limma package, a linear mixed model analysis provided in R, and the empirical Bayes approach to test for significant differences in gene expression between the second biopsy/blood sample and baseline, and between the third biopsy/blood sample and baseline \[[@pone.0190709.ref029]\]. To test for significantly differentially expressed genes between baseline and control samples, an unpaired t-test was performed with limma \[[@pone.0190709.ref029]\]. Patients were divided into two groups based on mucositis status (UM or NM), and significantly differentially expressed genes were detected with limma at each time point.

The FDR-adjusted P-values (≤0.05) were controlled with the Benjamini--Hochberg method \[[@pone.0190709.ref030]\] for each of the above tests.

### Hierarchical clustering {#sec015}

The GGE data set of all nine control samples and the eight TSCC samples were divided into eight subsets. These subsets were gene biotypes (defined as protein coding), pseudogenes, miRNA, rRNA, snoRNA, snRNA, linRNA, and antisense transcript. Each dataset was subjected to hierarchical clustering, where the Pearson correlation was used as a distance measure, and average linkage was used as the algorithm method \[[@pone.0190709.ref031]\].

Results {#sec016}
=======

Clinical characteristics of TSCC {#sec017}
--------------------------------

The pilot study design is shown in [Fig 1](#pone.0190709.g001){ref-type="fig"}. Three steps of intervention were planned during TSCC-specific standard therapy, which included RT and cisplatin treatments. We collected 32 biopsies and performed 32 blood draws (7 × 3 sample sets + 1 × 2 sample sets for TSCC and 9 × 1 sample set for controls).

Patient clinical characteristics and demographics are shown in [Table 1](#pone.0190709.t001){ref-type="table"}. Age was comparable between the control (age 58 years, range 47--78) and TSCC (age 63.5 years, range 51--69) groups. A trend towards male dominance was observed in the TSCC group (2 females among 8 patients), but not in the control group (4 females among 9 patients). Five of eight patients with TSCC were smokers, and four of the eight consumed alcohol. Tumor staging was evaluated according to the TMN system \[[@pone.0190709.ref021]\], and p16 overexpression was detected in six of eight tumors.

10.1371/journal.pone.0190709.t001

###### Patient characteristics and demographics upon enrollment in the study.

![](pone.0190709.t001){#pone.0190709.t001g}

  Patient      Age   Gender   ECOG[^a^](#t001fn001){ref-type="table-fn"}   Smoking[^b^](#t001fn002){ref-type="table-fn"}   Alcohol[^c^](#t001fn003){ref-type="table-fn"}   Staging[^d^](#t001fn004){ref-type="table-fn"}   p16[^e^](#t001fn005){ref-type="table-fn"}
  ------------ ----- -------- -------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- -------------------------------------------
  **TSCC01**   57    m        0                                            0                                               0                                               T1N2bM0                                         yes
  **TSCC03**   67    f        2                                            1                                               1                                               T1N0M0                                          no
  **TSCC04**   74    m        2                                            0                                               1                                               T1NxM0                                          no
  **TSCC05**   72    m        0                                            0                                               0                                               T1N2aM0                                         yes
  **TSCC06**   65    m        0                                            1                                               1                                               T1N1M0                                          yes
  **TSCC07**   59    m        1                                            1                                               1                                               T2N1M0                                          yes
  **TSCC08**   68    m        0                                            1                                               0                                               T4aN2cM0                                        yes
  **TSCC09**   56    f        0                                            1                                               0                                               T2N2cM0                                         yes

^a^Eastern Cooperative Oncology Group (ECOG) performance status at baseline

^b^Smoking categories: 0 = Non-smoker, 1 = smoked more than 10 cigarettes per day

^c^Alcohol categories: 0 = No alcohol consumption, 1 = consumed more than 3 units of alcohol per day

^d^TNM system for staging of cancer: T = size of primary tumor; N = presence and level of lymph node involvement; M = presence of distant metastasis (1)

^e^Overexpression of p16 indicates positive for HPV

The clinical data collected during RT are shown in [Table 2](#pone.0190709.t002){ref-type="table"}. After treatment initiation, the second biopsy was acquired at a median of 7 days (range 3--12), and the third biopsy was acquired at an average of 57 days (range 40--92). Two patients, TSCC06 and TSCC08, did not receive cisplatin. An average dose of 68.3 Gy (range 66--76) was applied to the tumors. According to the radiation schemes, a total dose of approximately 30--35 Gy was applied to the buccal mucosa bilaterally. At the time of the second biopsy, an average dose of 7.7 Gy (range 4.2--14.4) was applied. UM was detected in five patients and NM was detected in three patients. The median mucositis scores were 1.9 (range 0--3): 2.6 for the UM group and 0.7 for the NM group. We observed no signs of infection at the site of biopsy. All samples yielded valid gene expression profiles.

10.1371/journal.pone.0190709.t002

###### Patient clinical data during radiation treatment and at follow-up.

![](pone.0190709.t002){#pone.0190709.t002g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient      Total dose of radiation to tumor   Estimated dose of RT at biopsy site day7   Cisplatin (40 mg/m^2^)\   WHO[^a^](#t002fn002){ref-type="table-fn"}   Days from treatment start to second biopsy   Days from second to third biopsy
                                                                                             once weekly during RT                                                                                              
  ------------ ---------------------------------- ------------------------------------------ ------------------------- ------------------------------------------- -------------------------------------------- ----------------------------------
  **TSCC01**   66 Gy/33 fr                        4.2                                        yes                       3                                           3                                            53

  **TSCC03**   66 Gy/33 fr                        9.5                                        yes                       0                                           8                                            42

  **TSCC04**   68 Gy/34 fr                        9.3                                        yes                       1                                           8                                            dead

  **TSCC05**   68 Gy/33 fr                        14.4                                       yes                       2                                           12                                           41

  **TSCC06**   66 Gy/33 fr                        5.3                                        no                        1                                           4                                            40

  **TSCC07**   68 Gy/34 fr                        5.1                                        yes                       3                                           4                                            52

  **TSCC08**   76 Gy/56 fr                        6.9                                        no                        2                                           9                                            80

  **TSCC09**   68 Gy/34 fr                        7.2                                        yes                       3                                           6                                            92
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** Gy: Gray; fr: fractionated; WHO: World Health Organization

^a^mucositis stage, according to the WHO assessment scale, was measured weekly, during treatment and after, until mucositis dissolved \[[@pone.0190709.ref024]\].

Gene expression in mucosa and blood {#sec018}
-----------------------------------

The differentially expressed genes in mucosa ([Table 3](#pone.0190709.t003){ref-type="table"}) and blood ([Table 4](#pone.0190709.t004){ref-type="table"}) are annotated with a gene symbol, the fold change (FC), the adjusted p-value, the gene ontology terms (GO-terms), and the gene function.

10.1371/journal.pone.0190709.t003

###### Genes altered in mucosal tissue from patients with tonsil squamous cell carcinoma receiving radiation therapy.

![](pone.0190709.t003){#pone.0190709.t003g}

  Gene symbol                            FC      p-value    adj. p-value   Qualified Gene Onotology term                                                           Function
  -------------------------------------- ------- ---------- -------------- --------------------------------------------------------------------------------------- ---------------------------------------------------
  **Baseline**                                                                                                                                                     
  LIFR                                   -2.73   2.09e-05   0.019          Leukemia Inhibitory Factor Receptor Alpha                                               Cellular differentiation, proliferation, survival
  FKBP5                                  -2.48   0.00015    0.037          FK506 Binding Protein 5                                                                 Immune regulation, basic cellular processes
  SPARCL1                                -2.24   0.0002     0.041          SPARC Like 1                                                                            Cell adhesion, migration, and proliferation
  MS4A4E                                 -2.30   9.06e-06   0.018          Membrane Spanning 4-Domains A4E                                                         Cell surface signaling
  PDGFRA                                 -2.11   1.74e-06   0.010          Platelet Derived Growth Factor Receptor Alpha                                           Cell surface tyrosine kinase receptor
  RN7SL783P                              2.54    0.00010    0.031          pseudogene                                                                              Unknown function
  MTND5P8                                2.17    0.0002     0.04           pseudogene                                                                              Unknown function
  ABO                                    2.02    8.82e-07   0.001          Alpha 1-3-N-Acetylgalactosaminyltransferase                                             Enzyme, modifying surface glycoproteins
  **After seven days of radiotherapy**                                                                                                                             
  HIST1H3B                               -2.91   7.52e-08   0.000143       Histone Cluster 1, H3b                                                                  Transcription
  HIST1H2BM                              -2.75   1.6e-07    0.000251       Histone Cluster 1, H2bm                                                                 Transcription
  CYSLTR1                                -2.54   3.91e-05   0.0098         Cysteinyl Leukotriene Receptor 1                                                        Cell structure
  HIST1H3C                               -2.39   9.08e-06   0.0039         Histone Cluster 1, H3c                                                                  Transcription
  HIST1H3H                               -2.17   4.53e-08   0.000105       Histone Cluster 1, H3h                                                                  Transcription
  MOXD1                                  -2.16   6.19e-08   0.000128       Monooxygenase DBH Like 1                                                                Metabolism
  HIST1H1A                               -2.12   0.00016    0.022          Histone Cluster 1, H1a                                                                  Transcription
  HIST1H1B                               -2.09   1.05e-08   3.14e-05       Histone Cluster 1, H1b                                                                  Transcription
  MKI67                                  -2.00   2.58e-06   0.0016         Marker Of Proliferation Ki-67                                                           Transcription
  WDR63                                  2.67    1.09e-10   1.1e-06        WD Repeat Domain 63                                                                     Unknown
  MDM2                                   2.29    6.77e-11   4.26e-11       MDM2 oncogene, E3 ubiquitin protein ligase                                              Apoptosis
  EDA2R                                  2.26    8.38e-11   1.0e-06        Ectodysplasin A2 receptor                                                               Apoptosis
  POLH                                   2.17    3.22e-10   1.81e-06       Polymerase; DNA directed                                                                Transcription
  KRT16                                  2.15    0.00058    0.052          Keratin 16                                                                              Cell structure
  **Three weeks after RT cessation**                                                                                                                               
  ANKRD20A5P                             -3.56   2.90e-07   0.0026         Ankyrin Repeat Domain 20 Family Member A5                                               Pseudogene
  CYSLTR1                                -3.11   3.92e-06   0.0082         Cysteinyl Leukotriene Receptor 1                                                        Cell structure
  SCIN                                   -2.50   9.09e-05   0.044          Scinderin                                                                               Cell structure
  ANKRD20A11P                            -2.47   4.93e-05   0.033          Ankyrin Repeat Domain 20 Family Member A11                                              Pseudogene
  ANKRD20A9P                             -2.32   1.2e-06    0.0052         Ankyrin Repeat Domain 20 Family Member A9                                               Pseudogene
  CYP4F34P                               -2.28   4.1e-05    0.032          Cytochrome P450 Family 4 Subfamily F Member 34                                          Pseudogene
  TC2N                                   -2.13   6.47e-05   0.036          Tandem C2 Domains, Nuclear                                                              Metabolism
  IL1R2                                  -2.12   3.37e-07   0.0026         Interleukin 1 Receptor Type 2; cytokine receptor of the interleukin 1 receptor family   Immune response
  MIR31HG                                5.30    5.71e-05   0.035          Non-coding microRNA no 3                                                                Non-coding mi-RNA
  CCAT1                                  3.08    1.08e-05   0.018          Colon Cancer Associated Transcript 1                                                    Non-coding RNA
  PTPRZ1                                 2.93    0.000103   0.047          Protein Tyrosine Phosphatase, Receptor Type Z1                                          Transcription
  **NM versus UM**                                                                                                                                                 
  LY6G6C                                 -3.78   2.53e-06   0.0995         Lymphocyte Antigen-6 G6C                                                                Signal transduction Immune response

10.1371/journal.pone.0190709.t004

###### Genes altered in mononuclear cells of the blood from patients with tonsil squamous cell carcinoma receiving radiation therapy.

![](pone.0190709.t004){#pone.0190709.t004g}

  Gene symbol    FC      p-value    adj. p-value   Qualified Gene Onotology term                                 Function
  -------------- ------- ---------- -------------- ------------------------------------------------------------- -------------------------------
  **Baseline**                                                                                                   
  RNU6-620P      -11.8   1.48e-12   5.80e-08       RNA, U6 small nuclear 620, pseudogene                         pseudogene
  RNU6-422P      -3.77   3.03e-08   0.00022        RNA, U6 small nuclear 422, pseudogene                         pseudogene
  RNU6-737P      -3.36   1.34e-07   0.00034        RNA, U6 small nuclear 737, pseudogene                         pseudogene
  RNU6-795P      -2.85   2.82e-06   0.0024         RNA, U6 small nuclear 795, pseudogene                         pseudogene
  RPS7P2         -2.63   2.14e-07   0.00044        Ribosomal protein S7 pseudogene 2                             pseudogene
  AGAP9          -2.61   6.15e-06   0.0039         ArfGAP With GTPase Domain, Ankyrin Repeat And PH Domain 9     GTPase-activating
  RNU6-336P      -2.45   5.72e-08   0.00025        RNA, U6 small nuclear 336, pseudogene                         pseudogene
  OAZ1           -2.26   6.81e-06   0.0040         Ornithine decarboxylase antienzyme 1                          Cell growth and proliferation
  RPL23AP64      -2.19   0.00012    0.018          Ribosomal protein L23a pseudogene 64                          pseudogene
  RNU6-1162P     -2.06   2.02e-05   0.0068         RNA, U6 small nuclear 1162, pseudogene                        pseudogene
  CCDC144B       -2.02   0.00074    0.043          Coiled-Coil Domain Containing 144B                            pseudogene
  RN7SL432P      -2.02   5.37e-07   0.00088        RNA, 7SL, cytoplasmic 432, pseudogene                         pseudogene
  RNU6-622P      7.30    7.74e-09   8.62e-05       RNA, U6 Small Nuclear 622, Pseudogene                         pseudogene
  DUTP6          3.45    1.74e-06   0.0019         Deoxyuridine Triphosphatase Pseudogene 6                      pseudogene
  SSU72P8        3.44    1.07e-07   0.0014         RNA Polymerase II CTD Phosphatase Homolog, Pseudogene 8       pseudogene
  RNU6-919P      3.37    1.06e-05   0.0051         RNA, U6 Small Nuclear 919, Pseudogene                         pseudogene
  RPS6P15        3.01    2.82e-06   0.0024         Ribosomal Protein S6 Pseudogene 15                            pseudogene
  RN7SL748P      2.44    1.59e-05   0.0061         RNA, 7SL, Cytoplasmic 748, Pseudogene                         pseudogene
  RPL10P4        2.33    2.88e-07   0.00051        Ribosomal Protein L10 Pseudogene 4                            pseudogene
  RPL21P133      2.32    6.39e-07   0.0010         Ribosomal Protein L21 Pseudogene 133                          pseudogene
  RN7SL290P      2.22    1.06e-05   0.0051         RNA, 7SL, Cytoplasmic 290, Pseudogene                         pseudogene
  OR5M4P         2.21    4.97e-05   0.011          Olfactory Receptor Family 5 Subfamily M Member 4 Pseudogene   pseudogene
  RNU6-151P      2.19    1.58e-07   0.00036        RNA, U6 Small Nuclear 151, Pseudogene                         pseudogene
  RNU6-135P      2.19    1.29e-07   0.00034        RNA, U6 Small Nuclear 135, Pseudogene                         pseudogene
  RNA5SP116      2.18    0.00085    0.046          RNA, 5S Ribosomal Pseudogene 116                              pseudogene
  NUTM2D         2.13    0.00016    0.021          NUT family member 2D                                          unknown
  RNA5SP54       2.06    8.49e-08   0.00030        RNA, 5S Ribosomal Pseudogene 54                               pseudogene
  RN7SL865P      2.05    0.00074    0.043          RNA, 7SL, Cytoplasmic 865, Pseudogene                         pseudogene
  RPS29P8        2.00    8.69e-07   0.0012         Ribosomal Protein S29 Pseudogene 8                            pseudogene

Before RT was applied, eight genes were altered in patients with TSCC compared to controls ([Table 3](#pone.0190709.t003){ref-type="table"}). Five of these genes remained unaffected with subsequent therapy: *LIFR*, *FKBP5*, *SPARCL1*, *MS4A4E*, and *PDGFRA*.

In response to treatment, we found nine downregulated genes. Eight of these genes were in the histone cluster family, including *HIST1H3B*, *HIST1H2BM*, *HIST1H3C*, *HIST1H3H*, *HIST1H1A*, and *HIST1H1B*; and one, *MKI67*, was a marker of Ki-67 proliferation. Five genes were upregulated. Of these, two were related to apoptosis, *MDM2* and *EDA2R*, and one, *POLH*, encoded a transcriptional DNA-directed polymerase ([Table 3](#pone.0190709.t003){ref-type="table"}).

On day 21 after the last RT application, we found 11 altered genes compared to baseline ([Table 3](#pone.0190709.t003){ref-type="table"}). Most were pseudogenes, including *ANKRD20A5P*, *ANKRD20A11P*, *ANKRD20A9P*, and *CYP4F34P* (downregulated); and noncoding RNAs, *CCAT1* and *MIR31HG*. The *MIR31HG* RNA was upregulated only among patients with TSCC that received cisplatin. *IL1R2* (downregulated) encoded a cytokine receptor of the interleukin 1 receptor family. *SCIN* (downregulated) encoded a regulatory protein involved in exocytosis. Immunohistochemical analysis results ([Fig 2](#pone.0190709.g002){ref-type="fig"}) showed reduced expression in epithelial cells, but not in the salivary glands.

![Immunohistochemical analysis of mucosal tissue expression of scinderin.\
Oral buccal mucosa section (×15 magnification) stained with an *SCIN* antibody. (a) High scinderin expression is evident in mucosa from a control individual (patient CON05). (b) Low scinderin expression is evident in mucosa from a patient with tonsil squamous cell cancer (patient TSCC07); the biopsy was acquired Day20. *SCIN* encodes a regulatory protein involved in exocytosis and we expected to se downregulation in salivary gland tissue, however epithelial cells were heavily stained in the healthy control group.](pone.0190709.g002){#pone.0190709.g002}

When gene expression profiles of the buccal mucosa were compared between UM and NM samples, we found no differentially expressed genes (adjusted P \< 0.05) in either blood or mucosa. However, one gene, *LY6G6C*, tended to be expressed at low levels (FC -3.78; adj. P = 0.0995) in UM baseline biopsies **(**[Fig 3](#pone.0190709.g003){ref-type="fig"}, [Table 3](#pone.0190709.t003){ref-type="table"}).

![Expression of *LY6G6C* in mucosa.\
Dot plot shows expression of *LY6G6C*, at baseline (Day 0), after 7 days of RT (Day 7), and 20 days after the last RT session (Day 20), among patients that developed ulcerative mucositis (red) or mild/no mucositis (green), and in controls (blue). Patients with mild/ no mucositis exhibited an upregulation of *LY6G6C*. *LY6G6C* encodes a surface immunoregulatory protein expressed on mucosal dendritic cells.](pone.0190709.g003){#pone.0190709.g003}

We found 12 downregulated and 17 upregulated genes in blood samples from the TSCC group compared to the control group ([Table 4](#pone.0190709.t004){ref-type="table"}). These genes were dominated by small nuclear RNAs (snRNAs), e.g., *RNU6-620P* and *RNU6-622P*, and a dot plot of these two selected genes is shown in [Fig 4](#pone.0190709.g004){ref-type="fig"}.

![Expression of *RNU6-620P* and *RNU6-622P* in blood cells.\
Dot plot shows expression of *RNU6-620P* (FC-x11.8; P = 5.80e-80) and *RNU6-622P* (FCx7.3 P = 8.62e-05) at baseline (Day 0), after 7 days of RT (Day 7), and 20 days after the last RT session (Day 20), among patients that developed ulcerative mucositis (red) or mild/no mucositis (green). Expression in normal controls is indicated with blue circles. These genes encode small nuclear RNAs, which are non-protein coding genes. Patients with TSCC expressed a significant different level of both genes compared to healthy controls.](pone.0190709.g004){#pone.0190709.g004}

We clustered the expression levels of snRNAs, regardless of fold-changes according to P-value, and observed a distinct division between patients with TSCC and healthy controls ([Fig 5](#pone.0190709.g005){ref-type="fig"}). We found no differentially expressed genes in blood samples between baseline and day 7 or day 20.

![Small nuclear RNA (snRNA) clustered according to P value.\
The expression of snRNA regardless of fold change was clustered according to P value, showing a distinct division between patients with TSCC and healthy controls.](pone.0190709.g005){#pone.0190709.g005}

Discussion {#sec019}
==========

This study aimed to validate our clinical pilot study set-up and demonstrate its potential for identifying pathogenic variables or biomarkers for molecular mucositis. In response to RT, we identified several altered genes in the mucosa, but no differentially expressed genes in the blood cells. Furthermore, the identified genes were not correlated to the grade of clinical mucositis. Furthermore, we found that although all patients with TSCC were diagnosed with a localized solid epithelial tumor, and the biopsies from the study group was harvested from clinically healthy buccal mucosa, the mucosal tissue and blood cells had different gene profiles compared to healthy controls before RT.

RT effects on mucosal gene expression {#sec020}
-------------------------------------

Several studies have described the molecular effects of radiation on normal tissue, but no studies have described effects on gene expression levels \[[@pone.0190709.ref019]\]. Generally, short-term alterations include increased levels of p53 and other apoptotic markers (e.g., Bcl-2 and Mcl-1) \[[@pone.0190709.ref014],[@pone.0190709.ref032]\], increased numbers of inflammatory cells (CD68-positive macrophages and other leukocyte subtypes), and alterations in inflammatory markers (e.g., NF-kB and COX-2) \[[@pone.0190709.ref032]--[@pone.0190709.ref035]\]. The epithelium begins to regenerate after one week of radiation, confirmed by the identification of cell proliferation markers, Ki-67 and \[^3^H\]-TdR, and by the increased expression of keratins (keratins 1, 6, 10, 16) \[[@pone.0190709.ref036],[@pone.0190709.ref037]\]. Over the long term, RT caused different distribution patterns of adhesion molecules and macrophage subpopulations, compared to pretreatment specimens \[[@pone.0190709.ref038]\].

The present pilot study identified markers of apoptotic activity. *EDA2R* was upregulated in the mucosa 7 days after RT initiation, compared to its pretreatment status. *EDA2R* encodes the ectodysplasin A2 receptor, a transmembrane protein in the tumor necrosis factor receptor superfamily. Upon stimulation, this receptor activates the NF-ĸB and JNK apoptotic pathways \[[@pone.0190709.ref039]\]. In addition, six members of the histone cluster family were downregulated, which indicated DNA damage. Histones are basic nuclear proteins responsible for nucleosome structure. Previous studies in cell lines have described histone downregulation in response to RT \[[@pone.0190709.ref040]\].

In parallel, the *MDM2* oncogene (*MDM2*) was upregulated. *MDM2* encodes an E3 ubiquitin ligase, localized in the nucleus, and is regulated transcriptionally by p53. In turn, E3 ubiquitin ligase mediates the ubiquitination of p53, and thereby, inhibits p53-mediated cell-cycle arrest and apoptosis \[[@pone.0190709.ref041]\]. In addition, the upregulation of *POLH*, a polymerase that replicates UV-damaged DNA, indicated a DNA defense mechanism. Thus, we identified both inducers and inhibitors of apoptosis and DNA damage, consistent with findings reported in previous preclinical studies.

Proliferation-related genes were also altered. *MKI67*, which encodes Ki-67, a nuclear protein that is essential for cellular proliferation, was downregulated after 7 days of RT. This finding contrasted with findings from a previous study on human mucosa \[[@pone.0190709.ref032]\]. However, *KRT16* was upregulated. *KRT16* encodes keratin16, a protein characteristic of early differentiated epithelial cells. This short-term change indicated continuous epithelial proliferation \[[@pone.0190709.ref042]\]. This finding was also reported in a previous study \[[@pone.0190709.ref037]\].

*SCIN* encodes a calcium ion- and actin filament-binding protein with a regulatory function in exocytosis \[[@pone.0190709.ref043]\]. We expected *SCIN* to be associated with salivary gland function because of the connection to exocytosis function and prior studies have reported histological changes in radiated salivary glands, including atrophy, edema, cell death, and fibrous tissue formation \[[@pone.0190709.ref044]\]. However an immune histochemical stain for SCIN revealed that the presence was seen in the epithelial cells ([Fig 2](#pone.0190709.g002){ref-type="fig"}).

A potential biomarker for the grade of clinical mucositis {#sec021}
---------------------------------------------------------

When we compared samples from three patients with NM to samples from 4 patients with UM, we found that *LY6G6C* (lymphocyte antigen 6 complex, locus G6C) was upregulated (x3.78; P = 0.0995) in NM before treatment, although this finding was not statistically significant ([Fig 3](#pone.0190709.g003){ref-type="fig"}). *LY6G6C* belongs to a cluster of leukocyte antigen-6 genes linked to the major histocompatibility complex--class II. This complex is located at the cell surface, where it is involved in immune-mediated signal transduction.

In a previous study, we showed that two members of the major histocompatibility complex--class II gene family, *HLADR-B1* and *B5*, could potentially predict UM in patients with multiple myeloma \[[@pone.0190709.ref020]\]. We therefore hypothesize that HLA-based immunity protect against tissue inflammation during treatment in both these disease categories. Because mucositis may be considered an inflammatory state, those findings might add to our molecular understanding of why RT induces severe mucositis in some patients.

Pretreatment gene signature of TSCC {#sec022}
-----------------------------------

In mucosa, we found that TSCC induced a specific gene signature different from controls ([Table 3](#pone.0190709.t003){ref-type="table"}). In particular, we found that TSCC induced changes in the expression of leukemia inhibitor factor receptor-alpha (*LIFR*), platelet-derived growth factor receptor-alpha (*PDGFR*), and secreted protein acidic and cysteine rich-like protein (*SPARCL*) genes. First, this signature was present in clinically normal-appearing oral mucosa located at a distance from the tonsil tumor. Second, the signature was expressed independently of alcohol consumption, smoking habits, and p16 overexpression in the tumor, in addition to other clinical features. Third, this signature remained practically unchanged throughout RT.

*LIFR*, a transmembrane receptor protein of the type 1 cytokine receptor family, is involved in cellular differentiation, proliferation, and survival; moreover, it inhibits the p53 apoptotic pathway. Low expression has been detected in various human cancers \[[@pone.0190709.ref045]\]. However, *LIFR* has been identified as both a suppressor and a promoter of carcinogenesis. *PDGFR* encodes a cell-surface tyrosine kinase receptor that binds platelet-derived growth factor family members. The receptor complex activates pathways involved in cell migration and chemotaxis during wound healing \[[@pone.0190709.ref046]\]; additionally, mutations in *PDGFRA* play an active role in cancer development \[[@pone.0190709.ref047]\]. Finally, *SPARCL* is involved in extracellular matrix synthesis. It was downregulated in number human cancer types \[[@pone.0190709.ref048]\]. It remains unclear why these genes, which are involved in cellular differentiation, wound healing, and extracellular matrix formation, are downregulated in clinically normal-appearing mucosa acquired from patients with TSCC. Future studies should investigate whether this phenotype might indicate increased susceptibility to malignant transformation.

The GGE analysis of blood samples revealed a large array of snRNA-type pseudogenes. Of these, *RNU6-620P* was downregulated 11.8-fold (P = 5.80e-80) and *RNU6-622P* was upregulated 7.3-fold (P = 8.62e-05) compared to controls. A cluster analysis of the expression of snRNAs and other noncoding RNAs in the blood revealed that distinctly different clusters of noncoding RNAs were associated with TSCC and controls ([Fig 5](#pone.0190709.g005){ref-type="fig"}). The protein coding genes did not show the same distinction.

Conclusion {#sec023}
==========

In this pilot study, we described a gene signature expressed by mucosal tissue and circulating peripheral blood cells from patients with TSCC in response to RT. We chose to take the second biopsy before any macroscopic damage in order to gain insight into the molecular processes that underlie mucositis and to avoid harvesting disintegrates tissue dominated by inflammatory mediators. RT caused molecular alterations related to apoptosis, DNA damage, DNA repair, and proliferation. However, these alterations were independent of clinical mucositis severity. Furthermore we identified a potential protective biomarker for ulcerative mucositis. Based on these results, we concluded that our model was feasible, and the data will be useful in designing a prospective clinical validation trial for characterizing mucositis at the molecular level and identifying predictive biomarkers.

Accesion codes {#sec024}
==============

Phenotype data described in this manuscript was deposited at the NCBI Gene Expression Omnibus (GEO) repository under no GSE103412.
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